AAAAAA

   
Results: 1-10 |
Results: 10
Potential for therapy with AML-derived dendritic cells
Authors: Claxton, D Choudhury, A
Citation: D. Claxton et A. Choudhury, Potential for therapy with AML-derived dendritic cells, LEUKEMIA, 15(4), 2001, pp. 668-669
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia
Authors: Bibawi, S Abi-Said, D Fayad, L Anderlini, P Ueno, NT Mehra, R Khouri, I Giralt, S Gajewski, J Donato, M Claxton, D Braunschweig, I van Besien, K Andreeff, M Andersson, BS Estey, EH Champlin, R Przepiorka, D
Citation: S. Bibawi et al., Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia, AM J HEMAT, 67(4), 2001, pp. 227-233
Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma
Authors: Shimoni, A Smith, TL Aleman, A Weber, D Dimopoulos, M Anderlini, P Andersson, B Claxton, D Ueno, NT Khouri, I Donato, M Korbling, M Alexanian, R Champlin, R Giralt, S
Citation: A. Shimoni et al., Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma, BONE MAR TR, 27(8), 2001, pp. 821-828
Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study
Authors: Ravandi, F Kantarjian, H Cohen, A Davis, M O'Brien, S Anderlini, P Andersson, B Claxton, D Donato, M Gajewski, J Khouri, I Korbling, M Ueno, N deVos, D Champlin, R Giralt, S
Citation: F. Ravandi et al., Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study, BONE MAR TR, 27(12), 2001, pp. 1221-1225
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
Authors: Giralt, S Thall, PF Khouri, I Wang, XM Braunschweig, I Ippolitti, C Claxton, D Donato, M Bruton, J Cohen, A Davis, M Andersson, BS Anderlini, P Gajewski, J Kornblau, S Andreeff, M Przepiorka, D Ueno, NT Molldrem, J Champlin, R
Citation: S. Giralt et al., Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation, BLOOD, 97(3), 2001, pp. 631-637
Tacrolimus does not abrogate the increased risk of acute graft-versus-hostdisease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB I and HLA-DQB I
Authors: Przepiorka, D Saliba, R Cleary, K Fischer, H Tonai, R Fritsche, H Khouri, IF Folloder, J Ueno, NT Mehra, R Ippoliti, C Giralt, S Gajewski, J Donato, M Claxton, D Braunschweig, I van Besien, K Anderlini, P Andersson, BS Champlin, R
Citation: D. Przepiorka et al., Tacrolimus does not abrogate the increased risk of acute graft-versus-hostdisease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB I and HLA-DQB I, BIOL BLOOD, 6(2A), 2000, pp. 190-197
Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma
Authors: Przepiorka, D van Besien, K Khouri, I Hagemeister, F Samuels, B Folloder, J Ueno, NT Molldrem, J Mehra, R Korbling, M Giralt, S Gajewski, J Donato, M Cleary, K Claxton, D Braunschweig, I Andersson, B Anderlini, P Champlin, R
Citation: D. Przepiorka et al., Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma, ANN ONCOL, 10(5), 1999, pp. 527-532
Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation
Authors: Przepiorka, D Khouri, I Ippoliti, C Ueno, NT Mehra, R Korbling, M Giralt, S Gajewski, J Fischer, H Donato, M Cleary, K Claxton, D Chan, KW Braunschweig, I van Besien, K Andersson, BS Anderlini, P Champlin, R
Citation: D. Przepiorka et al., Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation, BONE MAR TR, 24(7), 1999, pp. 763-768
Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation
Authors: Przepiorka, D Smith, TL Folloder, J Khouri, I Ueno, NT Mehra, R Korbling, M Huh, YO Giralt, S Gajewski, J Donato, M Cleary, K Claxton, D Braunschweig, I van Besien, K Andersson, BS Anderlini, P Champlin, R
Citation: D. Przepiorka et al., Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation, BLOOD, 94(4), 1999, pp. 1465-1470
Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle-cell lymphoma
Authors: Khouri, IF Romaguera, J Kantarjian, H Palmer, JL Pugh, WC Korbling, M Hagemeister, F Samuels, B Rodriguez, A Giralt, S Younes, A Przepiorka, D Claxton, D Cabanillas, F Champlin, R
Citation: If. Khouri et al., Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle-cell lymphoma, J CL ONCOL, 16(12), 1998, pp. 3803-3809
Risultati: 1-10 |